Giovannangeli C, Perrouault L, Escudé C, Gryaznov S, Hélène C
Laboratoire de Biophysique Muséum National d'Histoire Naturelle, INSERM U.201-CNRS URA 481, Paris, France.
J Mol Biol. 1996 Aug 23;261(3):386-98. doi: 10.1006/jmbi.1996.0471.
Triplex-forming oligophosphoramidates containing thymines and cytosines or 5-methyl cytosines (5' T4CT4C6T 3') bind strongly to a 16 basepair oligopurine.oligopyrimidine sequence of HIV proviral DNA even at neutral pH. These triple-helical complexes formed with oligonucleotide analogues with N3'-->P5' phosphoramidate linkages are remarkably stable compared to oligonucleotides with natural phosphodiester linkages. In transcription assays the (T,C)-containing phosphoramidate oligomers induce an efficient arrest of both bacteriophage and eukaryotic transcriptional machineries under conditions where the isosequential phosphodiesters have no inhibitory effect. In both cases the RNA polymerase (SP6, T7 or Pol II) is physically blocked by the non-covalent triplex and RNA synthesis is stopped at the triplex site. However the eukaryotic transcription machinery is blocked more efficiently (at submicromolar concentration) than the bacteriophage polymerases. The analysis of the 3'-ends of the truncated transcripts provides evidence for differences in the termination patterns induced by the triplex barrier for the bacteriophage and the eukaryotic systems. This in vitro comparative study provides the basis for the rational design of strong transcriptional inhibitors. The efficient in vitro inhibition obtained using the phosphoramidate oligomers in the eukaryotic transcription assay makes them good candidates for the development of sequence-specific antigene agents.
含有胸腺嘧啶、胞嘧啶或5-甲基胞嘧啶(5'T4CT4C6T3')的三链形成寡磷酰胺在中性pH值下也能与HIV前病毒DNA的16个碱基对的寡嘌呤-寡嘧啶序列紧密结合。与具有天然磷酸二酯键的寡核苷酸相比,这些与具有N3'→P5'磷酰胺键的寡核苷酸类似物形成的三链螺旋复合物非常稳定。在转录试验中,含(T,C)的磷酰胺寡聚物在等序列磷酸二酯没有抑制作用的条件下,能有效阻止噬菌体和真核转录机制。在这两种情况下,RNA聚合酶(SP6、T7或Pol II)都被非共价三链体物理阻断,RNA合成在三链体位点停止。然而,真核转录机制比噬菌体聚合酶更有效地被阻断(在亚微摩尔浓度下)。对截短转录本3'末端的分析提供了证据,表明噬菌体和真核系统中三链体屏障诱导的终止模式存在差异。这项体外比较研究为合理设计强效转录抑制剂提供了基础。在真核转录试验中使用磷酰胺寡聚物获得的高效体外抑制作用使其成为开发序列特异性反基因药物的良好候选物。